<?xml version='1.0' encoding='utf-8'?>
<document id="24761818"><sentence text="The prevalence of opioid-related major potential drug-drug interactions and their impact on health care costs in chronic pain patients."><entity charOffset="18-24" id="DDI-PubMed.24761818.s1.e0" text="opioid" /></sentence><sentence text="Literature has shown that chronic pain patients prescribed opioids are at an increased risk for experiencing drug-drug interactions as a result of polypharmacy" /><sentence text=" In addition, chronic, noncancer pain patients who experience drug-drug interactions have been shown to have greater health care utilization and costs" /><sentence text=" However, no study has focused on the health economics of major clinically significant drug-drug interactions associated with long-acting opioids" /><sentence text="" /><sentence text="To (a) estimate the prevalence of major drug-drug interactions among patients prescribed a long-acting opioid and (b) evaluate the potential impact of major drug-drug interactions on health care costs"><entity charOffset="103-109" id="DDI-PubMed.24761818.s6.e0" text="opioid" /></sentence><sentence text="" /><sentence text="This study was a retrospective cohort analysis using claims data from the MarketScan Commercial Claims and Encounter Database between 2008 and 2010" /><sentence text=" Patients with at least 1 prescription for a long-acting opioid for â‰¥ 30 days were placed into cohorts according to the expected clinical impact of the potential drug-drug interaction: major versus none"><entity charOffset="57-63" id="DDI-PubMed.24761818.s9.e0" text="opioid" /></sentence><sentence text=" Propensity score matching was used to mitigate differences in baseline characteristics between the cohorts" /><sentence text=" Health care costs were based on payments for all covered health care services, which consisted of inpatient and outpatient medical, emergency department, and outpatient prescription costs" /><sentence text="" /><sentence text="Among 57,752 chronic, noncancer pain patients who met all inclusion and exclusion criteria, 5" /><sentence text="7% (3,302) were exposed to a potential major drug-drug interaction" /><sentence text=" The costs associated with a potential interaction versus no potential interaction were significantly more after baseline characteristics of the cohorts were normalized by propensity score matching" /><sentence text=" Monthly health care costs in the 90-day post-index period were significantly greater ($3,366 vs" /><sentence text=" $2,757, a $609 difference) in patients exposed to a potential drug-drug interaction of major clinical significance, compared with those not exposed to a drug-drug interaction" /><sentence text=" The higher health care costs were mainly driven by outpatient and inpatient medical costs" /><sentence text="" /><sentence text="Exposure to potential drug-drug interactions may result in unnecessary and unintended health care costs" /><sentence text=" Physicians should be made aware of commonly administered cytochrome P450 (CYP450) metabolized drugs in the chronic pain patient and consider prescribing non-CYP450 metabolized opioid and nonopioid analgesics" /><sentence text=" Managed care's use of utilization management tools to avoid these exposures may reduce costs" /><sentence text="" /></document>